Oyster Point Pharma attains primary endpoint in MYSTIC trial

A clinical-stage biopharmaceutical company, Oyster Point Pharma, Inc. recently announced positive results from its Phase 2 MYSTIC clinical study for Dry Eye Disease.

For the record, Oyster Point Pharma is focused upon discovering, developing, and commercializing novel pharmaceutical therapies to treat ocular surface diseases.

Dr. Preeya Gupta, Associate Professor, Ophthalmology at Duke University Eye Center and advisory board member at Oyster Point Pharma was quoted saying that the findings from the MYSTIC study validate the efficient mechanism of action of OC-O1 and its ability to promote natural tear production via the trigeminal parasympathetic pathway. Preeya Gupta added saying that there is a considerable need for a treatment option that can be delivered regularly through a novel route of administration that can stimulate natural tear film in patients along with addressing the underlying disease process.

The study indicated that OC-01 nasal spray was well-tolerated at the 2 doses tested. 24% of the subjects reported TEAE (treatment-emergent adverse event); which is 10 out of 41 in each nasal spray dose group. There were no serious adverse events related to study drug administration and no incidence of serious treatment-emergent adverse events (AE). The most common AE in the nasal spray groups were sneezing, headache, and blurry vision. All these events were minor in the nasal spray groups and were sorted by the next visit.

Dr. Jeffrey Nau, Chief Executive Officer of Oyster Point Pharma remarked that the company is exhilarated to further validate OC-01 nasal sprays’ ability to stimulate an increase in tear film production, which is sustained over the course of twice daily dosing for 84 days in patients with Dry Eye Disease from the MYSTIC study. Dr. Nau further added saying that they are looking forward to discussing top-line data from the Phase 3 study (ONSET 2) in Dry Eye Disease by mid-2020.

Source Credit: https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint